CA2932553A1 - Prostate cancer classification - Google Patents
Prostate cancer classification Download PDFInfo
- Publication number
- CA2932553A1 CA2932553A1 CA2932553A CA2932553A CA2932553A1 CA 2932553 A1 CA2932553 A1 CA 2932553A1 CA 2932553 A CA2932553 A CA 2932553A CA 2932553 A CA2932553 A CA 2932553A CA 2932553 A1 CA2932553 A1 CA 2932553A1
- Authority
- CA
- Canada
- Prior art keywords
- prostate cancer
- subject
- expression level
- sample
- srsf5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1322034.8 | 2013-12-12 | ||
| GBGB1322034.8A GB201322034D0 (en) | 2013-12-12 | 2013-12-12 | Prostate cancer classification |
| PCT/GB2014/053694 WO2015087088A2 (en) | 2013-12-12 | 2014-12-12 | Prostate cancer classification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2932553A1 true CA2932553A1 (en) | 2015-06-18 |
Family
ID=50030858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2932553A Abandoned CA2932553A1 (en) | 2013-12-12 | 2014-12-12 | Prostate cancer classification |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10196697B2 (enExample) |
| EP (1) | EP3080293B1 (enExample) |
| JP (1) | JP2017507320A (enExample) |
| KR (1) | KR20160098351A (enExample) |
| CN (1) | CN105940117A (enExample) |
| AU (1) | AU2014363173A1 (enExample) |
| BR (1) | BR112016013182A2 (enExample) |
| CA (1) | CA2932553A1 (enExample) |
| GB (1) | GB201322034D0 (enExample) |
| IL (1) | IL246067A0 (enExample) |
| MX (1) | MX2016007333A (enExample) |
| SG (1) | SG11201604508PA (enExample) |
| WO (1) | WO2015087088A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2885640B1 (en) | 2012-08-16 | 2018-07-18 | Genomedx Biosciences, Inc. | Prostate cancer prognostics using biomarkers |
| US11174518B2 (en) * | 2015-10-05 | 2021-11-16 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
| WO2017112860A1 (en) * | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | Distinguishing metastatic-lethal prostate cancer from indolent prostate cancer using methylation status of epigenetic markers |
| AU2017209307B2 (en) * | 2016-01-20 | 2023-06-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for screening and identifying clinically aggressive prostate cancer |
| EP3504348B1 (en) | 2016-08-24 | 2022-12-14 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| CA3055925A1 (en) * | 2017-03-09 | 2018-09-13 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| WO2019028285A2 (en) | 2017-08-04 | 2019-02-07 | Genomedx, Inc. | USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY |
| WO2019195658A1 (en) * | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
| CN109295208A (zh) * | 2018-10-26 | 2019-02-01 | 德阳市人民医院 | Pi15作为骨关节炎标志物的应用 |
| KR20210122275A (ko) * | 2019-01-30 | 2021-10-08 | 얀센 파마슈티카 엔.브이. | 분자 아형에 기초하여 전립선암을 치료하는 방법 |
| GB201917428D0 (en) * | 2019-11-29 | 2020-01-15 | Univ Newcastle | Prostate cancer diagnostic |
| CN111518908B (zh) * | 2020-05-18 | 2023-10-17 | 奥尔文泰生物科技(杭州)有限公司 | 尿液前列腺癌标志物组合及其在制备精准诊断试剂中的用途 |
| EP3960877A1 (en) * | 2020-08-31 | 2022-03-02 | Koninklijke Philips N.V. | Prediction of a response of a prostate cancer subject to therapy or personalization of therapy of a prostate cancer subject |
| EP3960876A1 (en) * | 2020-08-31 | 2022-03-02 | Koninklijke Philips N.V. | Prediction of a response of a prostate cancer subject to radiotherapy based on pde4d7 correlated genes |
| EP3960878A1 (en) * | 2020-08-31 | 2022-03-02 | Koninklijke Philips N.V. | Selection of a dose for radiotherapy of a prostate cancer subject |
| JP7477872B2 (ja) * | 2020-09-30 | 2024-05-07 | 国立大学法人大阪大学 | 癌に関連する新規バイオマーカー |
| CN113234820A (zh) * | 2021-04-29 | 2021-08-10 | 北京艾克伦医疗科技有限公司 | 鉴定前列腺癌状态的方法和试剂盒 |
| US20250109442A1 (en) * | 2022-01-13 | 2025-04-03 | Oslo Universitetssykehus Hf | Prostate cancer markers and uses thereof |
| EP4253567A1 (en) * | 2022-03-31 | 2023-10-04 | OncoAssure Limited | A method of predicting risk of an aggressive or recurrent cancer |
| CA3253049A1 (en) * | 2022-05-12 | 2023-11-16 | Veracyte, Inc. | PROGNOSIS AND TREATMENT OF MOLECULAR SUBTYPES OF PROSTATIC CANCER |
| CN116891523B (zh) * | 2023-05-24 | 2024-05-17 | 深圳晶蛋生物医药科技有限公司 | 一种trpm3截短体、包含其的细胞系及其用途 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989001050A1 (en) | 1987-07-31 | 1989-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Selective amplification of target polynucleotide sequences |
| CA2005589C (en) | 1988-12-16 | 2001-02-06 | Akzo Nobel Nv | Self-sustained, sequence replication system |
| US5437975A (en) | 1991-02-25 | 1995-08-01 | California Institute Of Biological Research | Consensus sequence primed polymerase chain reaction method for fingerprinting genomes |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US7220557B2 (en) | 1997-04-24 | 2007-05-22 | Human Genome Sciences, Inc. | METH1 polynucleotides |
| US8071072B2 (en) * | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| AU2002214576A1 (en) | 2000-10-13 | 2002-04-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Genes related to development of refractory prostate cancer |
| CA2429722A1 (en) * | 2000-11-28 | 2002-06-06 | Wyeth | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| WO2003009814A2 (en) | 2001-07-25 | 2003-02-06 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US20040029151A1 (en) | 2002-04-09 | 2004-02-12 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
| US20050032065A1 (en) | 2002-06-24 | 2005-02-10 | Afar Daniel E. H. | Methods of prognosis of prostate cancer |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| US20050259483A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Genes and polypeptides relating to prostate cancers |
| WO2004067726A2 (en) | 2003-01-29 | 2004-08-12 | Keck Graduate Institute | Isothermal reactions for the amplification of oligonucleotides |
| US20040223970A1 (en) | 2003-02-28 | 2004-11-11 | Daniel Afar | Antibodies against SLC15A2 and uses thereof |
| US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| EP1733047A2 (en) * | 2004-02-27 | 2006-12-20 | Oncotherapy Science, Inc. | Pin-prc transition genes |
| US7666595B2 (en) * | 2005-02-25 | 2010-02-23 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
| AU2006234897A1 (en) | 2005-03-16 | 2006-10-19 | Sidney Kimmel Cancer Center | Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures |
| JP2008538007A (ja) | 2005-04-15 | 2008-10-02 | ベクトン，ディッキンソン アンド カンパニー | 敗血症の診断 |
| EP1717320A1 (en) | 2005-04-26 | 2006-11-02 | TopoTarget Germany AG | Identification of human gene sequences of cancer antigens expressed in metastatic carcinoma and involved in metastasis formation, and their use in cancer diagnosis, prognosis and therapy |
| EP1934367B1 (en) | 2005-09-14 | 2010-11-03 | National Research Council of Canada | Molecular method for diagnosis of prostate cancer |
| US20070059753A1 (en) | 2005-09-15 | 2007-03-15 | Tatiana Vener | Detecting gene methylation |
| JP2009514555A (ja) | 2005-11-08 | 2009-04-09 | ユークリッド ダイアグノスティックス リミテッド ライアビリティー カンパニー | 癌評価の遺伝子関連ＣｐＧアイランドのメチル化アッセイのための材料と方法 |
| WO2008067065A2 (en) | 2006-10-19 | 2008-06-05 | Shiv Srivastava | Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers |
| WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| US20110045464A1 (en) | 2007-01-10 | 2011-02-24 | Henry Ford Health System | Methods and compositions for identification of prostate cancer markers |
| CA2680692A1 (en) | 2007-03-30 | 2008-10-09 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for identification, monitoring, and treatment of prostate cancer |
| WO2009028158A1 (en) | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| WO2009151503A2 (en) | 2008-04-10 | 2009-12-17 | University Of Florida Research Foundation, Inc. | Compositions and methods for the treatment of a neoplasia |
| WO2009126271A1 (en) | 2008-04-11 | 2009-10-15 | China Synthetic Rubber Corporation | Methods, agents and kits for the detection of cancer |
| AU2009253675A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US20090298082A1 (en) | 2008-05-30 | 2009-12-03 | Klee George G | Biomarker panels for predicting prostate cancer outcomes |
| EP2315858A2 (en) | 2008-07-08 | 2011-05-04 | Source Precision Medicine, Inc. | Gene expression profiling for predicting the survivability of prostate cancer subjects |
| AU2009270851A1 (en) | 2008-07-16 | 2010-01-21 | Dana-Farber Cancer Institute, Inc. | Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof |
| US20100055705A1 (en) | 2008-08-29 | 2010-03-04 | Wilson Gerald M | Compositions and methods for diagnosing and treating cancer |
| US7888035B2 (en) | 2008-10-30 | 2011-02-15 | Caris Mpi, Inc. | Methods for assessing RNA patterns |
| CN102308212A (zh) | 2008-12-04 | 2012-01-04 | 加利福尼亚大学董事会 | 用于确定前列腺癌诊断和预后的材料和方法 |
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| ES2700877T3 (es) | 2009-05-12 | 2019-02-19 | Koninklijke Philips Nv | Fosfodiesterasa 4D7 como marcador de cáncer de próstata |
| KR102110469B1 (ko) | 2009-05-12 | 2020-05-14 | 코닌클리케 필립스 엔.브이. | 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7 |
| WO2010139711A1 (en) | 2009-06-04 | 2010-12-09 | Metanomics Health Gmbh | Means and methods for diagnosing prostate carcinomas |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| EP2309273B1 (en) | 2009-09-16 | 2016-05-18 | ZEILLINGER, Robert | Novel tumor marker determination |
| WO2011068839A1 (en) | 2009-12-01 | 2011-06-09 | Compendia Bioscience, Inc. | Classification of cancers |
| WO2011094233A1 (en) | 2010-01-26 | 2011-08-04 | The Johns Hopkins University | Methods of disease classification or prognosis for prostate cancer based on expression of cancer/testis antigens |
| US20130058925A1 (en) | 2010-02-26 | 2013-03-07 | Board Of Regents, The University Of Texas System | Epithelial biomarkers for cancer prognosis |
| CN105601727B (zh) | 2010-03-11 | 2020-01-10 | 肿瘤疗法科学股份有限公司 | Hjurp肽及包含它们的疫苗 |
| CA2836725A1 (en) | 2010-06-01 | 2011-12-08 | Indiana University Research And Technology Corporation | Materials and methods for diagnosing and predicting the course of prostate cancer |
| EP3812469A1 (en) | 2010-07-07 | 2021-04-28 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| US20130190310A1 (en) | 2010-07-26 | 2013-07-25 | The Johns Hopkins University | Mig6 and therapeutic efficacy |
| IL243203A (en) | 2010-07-27 | 2017-04-30 | Genomic Health Inc | Method for using gene expression to determine prognosis of prostate cancer |
| US9605319B2 (en) | 2010-08-30 | 2017-03-28 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| EP2702177B1 (en) | 2011-04-28 | 2017-04-12 | New York University | Genomic signatures of metastasis in prostate cancer |
| AU2012275500A1 (en) * | 2011-06-27 | 2014-01-16 | Dana-Farber Cancer Institute, Inc. | Signatures and determinants associated with prostate cancer progression and methods of use thereof |
| US20130079241A1 (en) * | 2011-09-15 | 2013-03-28 | Jianhua Luo | Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse |
| GB201206209D0 (en) | 2012-04-06 | 2012-05-23 | Univ Leuven Kath | Marker gene based diagnosis, staging and prognosis of prostate caner |
| AU2012358238B2 (en) | 2011-12-22 | 2017-12-07 | C. Frank Bennett | Methods for modulating Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1(MALAT-1) expression |
| DK3179393T3 (da) | 2012-01-31 | 2020-07-27 | Genomic Health Inc | Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft |
| TW201343920A (zh) | 2012-03-29 | 2013-11-01 | 財團法人國家衛生研究院 | 預測前列腺癌預後之分子標記、方法與套組 |
| BR102012007246A2 (pt) | 2012-03-30 | 2016-02-10 | Fundação Antonio Prudente | métodos para prognóstico e classificação de resultados de um evento |
| US20130288967A1 (en) | 2012-04-25 | 2013-10-31 | Euclid Diagnostics Llc | Materials and methods for cancer diagnosis by evaluation of the methylation status of cpg islands on chromosomes 6 and 8 |
| CN103146688B (zh) | 2012-09-12 | 2015-05-13 | 上海长海医院 | 长链非编码rna作为疾病诊断血液分子标志物的应用 |
-
2013
- 2013-12-12 GB GBGB1322034.8A patent/GB201322034D0/en not_active Ceased
-
2014
- 2014-12-12 EP EP14814697.0A patent/EP3080293B1/en active Active
- 2014-12-12 BR BR112016013182A patent/BR112016013182A2/pt not_active Application Discontinuation
- 2014-12-12 CN CN201480074318.2A patent/CN105940117A/zh active Pending
- 2014-12-12 US US15/103,770 patent/US10196697B2/en not_active Expired - Fee Related
- 2014-12-12 CA CA2932553A patent/CA2932553A1/en not_active Abandoned
- 2014-12-12 JP JP2016538689A patent/JP2017507320A/ja active Pending
- 2014-12-12 KR KR1020167018629A patent/KR20160098351A/ko not_active Withdrawn
- 2014-12-12 WO PCT/GB2014/053694 patent/WO2015087088A2/en not_active Ceased
- 2014-12-12 SG SG11201604508PA patent/SG11201604508PA/en unknown
- 2014-12-12 MX MX2016007333A patent/MX2016007333A/es unknown
- 2014-12-12 AU AU2014363173A patent/AU2014363173A1/en not_active Abandoned
-
2016
- 2016-06-06 IL IL246067A patent/IL246067A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160098351A (ko) | 2016-08-18 |
| WO2015087088A2 (en) | 2015-06-18 |
| AU2014363173A1 (en) | 2016-07-07 |
| EP3080293A2 (en) | 2016-10-19 |
| CN105940117A (zh) | 2016-09-14 |
| BR112016013182A2 (pt) | 2017-09-26 |
| GB201322034D0 (en) | 2014-01-29 |
| US20160312294A1 (en) | 2016-10-27 |
| IL246067A0 (en) | 2016-07-31 |
| WO2015087088A3 (en) | 2015-09-17 |
| MX2016007333A (es) | 2016-10-13 |
| JP2017507320A (ja) | 2017-03-16 |
| SG11201604508PA (en) | 2016-07-28 |
| US10196697B2 (en) | 2019-02-05 |
| EP3080293B1 (en) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3080293B1 (en) | Prostate cancer classification | |
| Bibikova et al. | Expression signatures that correlated with Gleason score and relapse in prostate cancer | |
| Valdes-Mora et al. | Prostate cancer epigenetic biomarkers: next-generation technologies | |
| AU2019250606B2 (en) | Improved classification and prognosis of prostate cancer | |
| EP3310927B1 (en) | Gene signatures predictive of metastatic disease | |
| WO2008104543A2 (en) | Method for predicting the occurrence of metastasis in breast cancer patients | |
| Kanda et al. | Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer | |
| CA2961725C (en) | A method of predicting risk of recurrence of cancer | |
| WO2015073949A1 (en) | Method of subtyping high-grade bladder cancer and uses thereof | |
| WO2012125411A1 (en) | Methods of predicting prognosis in cancer | |
| Strand et al. | RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy | |
| Koumarianou et al. | Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression | |
| US20160355889A1 (en) | Method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels | |
| Amato et al. | RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes | |
| Farkas et al. | Epigenetic changes as prognostic predictors in endometrial carcinomas | |
| Kim et al. | Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer | |
| Huang et al. | A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival | |
| CA2939924A1 (en) | Method and composition for diagnosis of aggressive prostate cancer | |
| Goh et al. | Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer | |
| US20230416841A1 (en) | Inferring transcription factor activity from dna methylation and its application as a biomarker | |
| Moğul et al. | The PD-L1 Promoter Methylation Predicts Gene And Protein Expression Levels in Urothelial Carcinoma | |
| Snyder et al. | Discovery and Validation of Clinically Relevant Long Non-Coding RNAs in Colorectal Cancer. Cancers 2022, 14, 3866 | |
| Wang et al. | Effect of upregulation of DD3 on early detection and prognosis in prostate cancer | |
| Mazumder et al. | Molecular and cellular approaches to patient management in oncology | |
| Baehner | and Predictive Assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20181212 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: T-6-6-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250102 |